journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/28238599/service-review-improving-breast-cancer-care-in-tanzania
#1
Susan Mayor
No abstract text is available yet for this article.
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238598/carcinoid-syndrome-in-neuroendocrine-tumors-a-prognostic-effect
#2
Michel Ducreux
No abstract text is available yet for this article.
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238597/optimising-haemopoietic-cell-transplantation
#3
Priya Venkatesan
No abstract text is available yet for this article.
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238596/less-is-more-de-intensification-of-therapy-for-early-stage-her2-positive-breast-cancer
#4
Aju Mathew, Adam Brufsky
No abstract text is available yet for this article.
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238595/pembrolizumab-as-second-line-treatment-for-urothelial-cancer
#5
Fiona Mitchell
No abstract text is available yet for this article.
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238594/scalp-cooling-and-hair-loss-during-breast-cancer-chemotherapy
#6
Vicki Brower
No abstract text is available yet for this article.
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238593/her2-enriched-subtype-as-a-predictor-of-pathological-complete-response-following-trastuzumab-and-lapatinib-without-chemotherapy-in-early-stage-her2-positive-breast-cancer-pamela-an-open-label-single-group-multicentre-phase-2-trial
#7
Antonio Llombart-Cussac, Javier Cortés, Laia Paré, Patricia Galván, Begoña Bermejo, Noelia Martínez, Maria Vidal, Sònia Pernas, Rafael López, Montserrat Muñoz, Paolo Nuciforo, Serafín Morales, Mafalda Oliveira, Lorena de la Peña, Alexandra Peláez, Aleix Prat
BACKGROUND: HER2-positive breast cancer consists of four intrinsic molecular subtypes-luminal A, luminal B, HER2-enriched, and basal-like-and a normal-like subtype, with the HER2-enriched subtype having the highest activation of the EGFR-HER2 pathway. We aimed to test the hypothesis that patients with the HER2-enriched subtype benefit the most from dual HER2 blockade. METHODS: PAMELA is an open-label, single-group, phase 2 trial done in 19 hospitals in Spain. We recruited female patients aged at least 18 years with previously untreated, centrally confirmed HER2-positive, stage I-IIIA invasive breast cancer regardless of hormone receptor status...
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28238592/frequency-of-carcinoid-syndrome-at-neuroendocrine-tumour-diagnosis-a-population-based-study
#8
Daniel M Halperin, Chan Shen, Arvind Dasari, Ying Xu, Yiyi Chu, Shouhao Zhou, Ya-Chen Tina Shih, James C Yao
BACKGROUND: Neuroendocrine tumours (NETs) can secrete bioactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and diarrhoea. However, carcinoid syndrome frequency in the NET population has never been rigorously assessed, nor has its relationship to presenting clinicopathological characteristics. This analysis assessed the proportion of patients with NETs and carcinoid syndrome in the USA and associated clinical factors. METHODS: We identified patients (≥65 years of age) from the Surveillance, Epidemiology, and End Results-Medicare database, excluding those with pancreatic tumours or small-cell or large-cell lung cancer, as well as those without complete data...
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28237632/predicting-outcomes-after-a-positive-interim-fdg-pet-scan-in-advanced-hodgkin-s-lymphoma
#9
Michael Crump
No abstract text is available yet for this article.
February 22, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28236583/progression-free-survival-of-early-interim-pet-positive-patients-with-advanced-stage-hodgkin-s-lymphoma-treated-with-beacoppescalated-alone-or-in-combination-with-rituximab-hd18-an-open-label-international-randomised-phase-3-study-by-the-german-hodgkin-study
#10
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Markova, Michaela Feuring-Buske, Julia Meissner, Ulrich Dührsen, Helmut Ostermann, Ulrich Keller, Georg Maschmeyer, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Hans Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Andreas Engert
BACKGROUND: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring in terms of predicting long-term treatment outcome in patients with Hodgkin's lymphoma. We therefore hypothesised that early interim PET-imaging after two courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) might be suitable for guiding treatment in patients with advanced stage Hodgkin's lymphoma...
February 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28223062/nivolumab-for-previously-treated-unresectable-metastatic-anal-cancer-nci9673-a-multicentre-single-arm-phase-2-study
#11
Van K Morris, Mohamed E Salem, Halla Nimeiri, Syma Iqbal, Preet Singh, Kristen Ciombor, Blase Polite, Dustin Deming, Emily Chan, James L Wade, Lianchun Xiao, Tanios Bekaii-Saab, Luis Vence, Jorge Blando, Armeen Mahvash, Wai Chin Foo, Chimela Ohaji, Manolo Pasia, Gail Bland, Aki Ohinata, Jane Rogers, Amir Mehdizadeh, Kimberly Banks, Richard Lanman, Robert A Wolff, Howard Streicher, James Allison, Padmanee Sharma, Cathy Eng
BACKGROUND: Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with infection by human papillomavirus (HPV). No consensus treatment approach exists for the treatment of metastatic disease. Because intratumoral HPV oncoproteins upregulate immune checkpoint proteins such as PD-1 to evade immune-mediated cytotoxicity, we did a trial of the anti-PD-1 antibody nivolumab for patients with metastatic SCCA. METHODS: We did this single-arm, multicentre, phase 2 trial at ten academic centres in the USA...
February 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28223061/anal-cancer-from-an-orphan-disease-to-a-curable-malignancy
#12
Stefano Cascinu
No abstract text is available yet for this article.
February 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28223060/reduced-carginogens-found-in-e-cigarette-users
#13
Talha Khan Burki
No abstract text is available yet for this article.
February 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28215927/will-drug-companies-price-transparency-efforts-fall-short
#14
Bryant Furlow
No abstract text is available yet for this article.
February 16, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28209299/classic-cytotoxic-drugs-a-narrow-path-for-regulatory-approval
#15
Xavier Pivot
No abstract text is available yet for this article.
February 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28209298/utidelone-plus-capecitabine-versus-capecitabine-alone-for-heavily-pretreated-metastatic-breast-cancer-refractory-to-anthracyclines-and-taxanes-a-multicentre-open-label-superiority-phase-3-randomised-controlled-trial
#16
Pin Zhang, Tao Sun, Qingyuan Zhang, Zhongyu Yuan, Zefei Jiang, Xiao Jia Wang, Shude Cui, Yuee Teng, Xi-Chun Hu, Junlan Yang, Hongming Pan, Zhongsheng Tong, Huiping Li, Qiang Yao, Yongsheng Wang, Yongmei Yin, Ping Sun, Hong Zheng, Jing Cheng, Jinsong Lu, Baochun Zhang, Cuizhi Geng, Jian Liu, Roujun Peng, Min Yan, Shaohua Zhang, Jian Huang, Li Tang, Rongguo Qiu, Binghe Xu
BACKGROUND: Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus capecitabine alone in patients with metastatic breast cancer. METHODS: We did a multicentre, open-label, superiority, phase 3, randomised controlled trial in 26 hospitals in China. Eligible participants were female patients with metastatic breast cancer refractory to anthracycline and taxane chemotherapy regimens...
February 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28209297/anal-cancer-leading-the-way
#17
Angelita Habr-Gama, Guilherme Pagin São Julião, Rodrigo Oliva Perez
No abstract text is available yet for this article.
February 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28209296/best-time-to-assess-complete-clinical-response-after-chemoradiotherapy-in-squamous-cell-carcinoma-of-the-anus-act-ii-a-post-hoc-analysis-of-randomised-controlled-phase-3-trial
#18
Robert Glynne-Jones, David Sebag-Montefiore, Helen M Meadows, David Cunningham, Rubina Begum, Fawzi Adab, Kim Benstead, Robert J Harte, Jill Stewart, Sandy Beare, Allan Hackshaw, Latha Kadalayil
BACKGROUND: Guidelines for anal cancer recommend assessment of response at 6-12 weeks after starting treatment. Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after chemoradiotherapy. METHODS: The previously reported ACT II trial was a phase 3 randomised trial of patients of any age with newly diagnosed, histologically confirmed, squamous cell carcinoma of the anus without metastatic disease from 59 centres in the UK...
February 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28190766/cancer-care-on-palm-island-australia
#19
Georgina Kenyon
No abstract text is available yet for this article.
February 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28190765/short-course-radiotherapy-with-delayed-surgery-for-rectal-cancer-a-third-option
#20
Krzysztof Bujko, Rafał Sopyło
No abstract text is available yet for this article.
February 9, 2017: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"